medigraphic.com
ISSN 1729-519X (Print)

2014, Number 2

<< Back Next >>

Revista Habanera de Ciencias Médicas 2014; 13 (2)

Chemotherapy in avanced lung cancer in patients of 60 years and older at hospital benefico juridico (2008-2011)

Díaz TM, Cayón EI, Crespo DTT, Fernández NL, Rosas VC

Language: Spanish
References: 19
Page: 227-237
PDF size: 165.66 Kb.


ABSTRACT

Introduction: lung cancer is one of the most frequent malignant diseases generally diagnosed at advanced stages, where the main treatment is Chemotherapy.
Objective: to characterize the clinical-radiological evolution of 60 years old and older patients suffering from lung cancer not small cells in III B and IV stages, who were treated with polychemoterapy.
Materials and Method: a descriptive, retrospective study was done in Benéfico Jurìdico Hospital from January 2008 to December 2011. The sample was composed of 54 patients whose information was obtained from their clinical records and Tumor Committee records. Social demographic and clinical variables studied were: Sex, age, tumor stage, clinical symptoms, general conditions, radiological evolution, and general response to treatment. The higher percentage of studied patients was in the group of 60 to 69 years, and the male sex stood out.
Results: a 66.7 % of the sample ware men and the highest rate (65%) were between 60 and 69 years old. A 55.5 % of all cases were classified in a IV stage. There was a significant improvement of the dyspnea, the lost of weight, cough, expectoration and thoracic pain after treatment. In an III B stage, before and after treatment, degree of activity got worse after treatment, prevailing degree of activity 2. In both stages the stable illness prevailed as a radiologic response.
Conclusions: lung carcinoma still being more frequent in over 60 years old men. In more than a half of all cases it is diagnosed at advanced stages, were chemotherapy occasionally is able to improve the symptoms, with a poor influence on the degree of activity. Stability, as radiological response, prevailed.


REFERENCES

  1. Moreno de La Santa Baraja P, Corbacho D, Iglesias F, Gómez C, Romero C, Labres C, et al. Protocolo de Tratamiento del Cáncer de Pulmón en estadio III B Arch Bronconeumol. 2007;40(suppl 2):1-151.

  2. Álvarez Sintes R. Afecciones Respiratorias más frecuentes. En: Álvarez Sintes R, Díaz Alonso G, Salas Mainegras I, Lemus Lago ER, Batista Moliner R. Temas de Medicina General Integral. La Habana: Ciencias Médicas; 2001. p. 505-11.

  3. Sánchez de Cos Escuín Julio. El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. Arch Bronconeumol. 2009;45(07):341-8.

  4. Fuente Alonso C de la, Regueiro C, Cajón E, Varcárcel F, García Menocal MI, et al. Temas: Comparación radio quimioterapia concomitante con Taxol y Vincristina en el carcinoma de pulmón no microcítico localmente avanzado. Arch Bronconeumol. 2004;40(suppl 2):1-151.

  5. Laack E, Mende T, Dürk H, Kniba M, Dickgreber N, et al. Combinación de quimioterapia con gencitabine, vinorelbina y cisplatino en cáncer de pulmón de células no pequeñas: un ensayo fase II. European Journal of Cancer. 2008;2:331-7.

  6. Gridelli C, Maione P, Rossi A. Chemotherapy and targeted therapy for older patients with advanced non-small cell lung cancer. Am Soc Clin Oncol Ed Book. 2009;283-287.

  7. Quoix EA, Oster J, Westeel V, Ginsberg RJ, Vokess EE. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:5s(suppl; abstr 2).

  8. Estrada Trigueros G, Comeche L, López Encuentra A, Montoso Zulueta J, González Garrido F. Carcinoma broncogenico 2000- 2001. Características y supervivencia global. Arch Bronconeumol. 2007;43(11):594-98.

  9. Mederos Curbelo ON, Leal Mursuli A, Olivera Sandoval O, Barrera Ortega JC, Romero Díaz CA. El cáncer de pulmón y la creación de grupos multidisciplinarios en cirugía torácica. Rev Cubana Cirug. 2004;43(3-4).

  10. Zang EA, Wynder L: Differences in lung cancer risk between men and woman. Examination of evidences. J Nati cancer III. 1996;88:183-92A.

  11. Beckles M A, Spiro S G, Colice G L, HarringtonD, Belani CP. Initial evaluation of the patient with lung cancer. Symptoms, signs, laboratory test and paraneoplastic syndromes. Chest. 2008;123(suppl 1):97-104.

  12. Sánchez de Cos Escuín J, Hurtado Delgado I, Cabrera Rodríguez J, Jiménez López M, Disdier V, Miranda Riesgo A. Carcinoma de pulmón no microcítico. Estadios IIIB y IV. Resultados de tratamientos con RQT y análisis de factores pronósticos. Arch Bronconeumol. 2007;43(7):358_65.

  13. Gullón Blanco A, Suárez Toste I, Fernández Álvarez R, Rubinas Cuadrado G, Medina González A, et al. Quimioterapia y Supervivencia en el carcinoma bronco génico no macrobiótico en estadios avanzados: ¿Está justificado el nihilismo d los neumólogos? Arch Broconeumol. 2006;42:(6):273-7.

  14. Sánchez de Cos Escuin J. Nuevas dianas y estrategias terapéuticas en el cáncer de pulmón. Unidad de Neumología. Hospital San Pedro de Alcántara. Cáceres. Arch Bronconeumol. 2002;38(8):386-91.

  15. Rainsey SD, Howlader N, Etsioni RD, DONATO B: Chemotherapy use, outcomer, and costs for older persons with advanced non- small cell lung cancer: Evidens from surveillance, epidemiology and end nesielts-Medicare. J Clin Oncol. 2007;22(24):971-8.

  16. Rodríguez C, Guevara V, Ville R. Evaluación de síntomas en un grupo de pacientes oncológicos en fase terminal. Trabajo presentado en el Congreso Internacional de Dolor y Cuidados Paliativos. México, Nov 1994. En: Memorias del congreso. México, DF; 1994.

  17. Oken MM, Creech RH, Tormey, DC, Horton J, Davis TE, Back PB, Kelly MJ. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.

  18. Paredes López D, Fuentes Valdés E, Collado Otero JC. Resultados del tratamiento inductivos en el cáncer de pulmón de células no pequeñas localmente avanzado: Rev Cubana Cirugía [revista en Internet]. 2007 [citado julio 2011];46(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 74932007000300002&lng=es&nrm=iso&tlng=es

  19. Vokes EE, Leopold KA, Herdon J.Johnson DH, Pfister DG, Brown J. Investigations of new drugs in combination with Cisplatin in stage III non- small cell lung cancer. Sem Oncol. 2007;24(suppl 8):842-5.




2020     |     www.medigraphic.com